HC Wainwright Comments on BioCryst Pharmaceuticals, Inc.'s FY2027 Earnings (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating) – Stock analysts at HC Wainwright decreased their FY2027 earnings per share estimates for BioCryst Pharmaceuticals in a research note issued on Thursday, May 4th. HC Wainwright analyst A. Fein now expects that the biotechnology company will post earnings of $1.16 per share for the year, down from […]

Related Keywords

Canada ,Zurcher Kantonalbank Zurich Cantonalbank ,Grimes Company Inc ,Ensign Peak Advisors Inc ,Huntington National Bank ,News Ratings For Biocryst Pharmaceuticals Daily ,Institutional Trading Of Biocryst Pharmaceuticals ,Group Plc ,Biocryst Pharmaceuticals ,Needham Company ,Nasdaq ,Biocryst Pharmaceuticals Price Performance ,Royal Bank ,Biocryst Pharmaceuticals Inc ,Get Rating ,Biocryst Pharmaceutical ,Cryst Pharmaceuticals ,National Bank ,Kantonalbank Zurich Cantonalbank ,General Group Plc ,Peak Advisors Inc ,Biocryst Pharmaceuticals Daily ,Nasdaq Bcrx ,Bcrx ,Medical ,09058v10 ,Earnings Estimates ,Hc Wainwright ,